RE:RE:RE:PD-(L)1 checkpoint inhibitors to reach $58 Billion by 2025 Regarding the short question.
Not my bag at all. Never have shorted, never will.
imho, the whole process should be banned as it is in some countries.
Saying that. I'm not certain,but I believe the shorting rules are easier on the Nas than the TSX.
lower price limits & various margin ratios.
Getting rid of shorting would substantially help Onc(y) shareprice.
and certainly more than a few of the FUDsters on these sites.
still back to basics, Onc needs to get Pela to market.
The recen5 development pointed out by notable,, re Roche. I don't know enough to comment.
Organically it seems to be good news.certainly not bad news.
As a side, that is yet another interesting example of many things going on which could directly effect Onc success.
In any situation there are many sides to a story. Adding additional layers.
Specifically with Onc , there is information we know. Public News & corporate web site.
there is infotmation we can look at as relivent, with ample speculations.
and....could be the largest pool of " stuff"....things happening we not only don't know about, but can't possibly predict.
The PanCan precision promise deal came out of the blue
No sooner was the public announcement, they PanCan , cancelled all of their future precicion promise opportunities.
The Roche recent approval? Could be a huge help for onc.or could mean nothing at all.
Obviously Roche has been working on that for a long time.
As I said, on the surface it looks to be only good news.
onc is heavily involved with Roche , Gobblet trials. Tecentriq being one of the cotherapy drugs.
Stay tuned